FIELD : biotechnology.SUBSTANCE : invention relates to a new GLP-1/glucagon receptor agonist, and can be used in medicine. Said agonist of the present invention is represented by a derivative of glucagon including a number of amino acid substitutions and in the structure of which an additional lipophilic group and at least 3 negatively charged groups are introduced.EFFECT : in comparison with the known analogues, the glucagon derivative of the present invention has an increased stability and an increased half-washout period from the body.16 cl, 80 ex, 6 tbl